Highlighting 'Pay For Delay' Concerns

Law360, New York (February 3, 2012, 1:28 PM EST) -- The U.S. Federal Trade Commission (FTC) has recently released two reports relating to the pharmaceutical industry. A significant theme in both reports is a concern that brand-name pharmaceutical companies are using the threat of launching an authorized generic to make deals that delay generic entry.

These reports shine a spotlight on the interplay between authorized generics and pharmaceutical patent settlements, and indicate strong FTC opposition to a practice that has never been found unlawful.

Report on Authorized Generics

On Aug. 31, 2011, the FTC issued its...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.